Terlipressin EVER Pharma is indicated for the treatment of bleeding oesophageal varices and Hepato-renal syndrome type 1.
NICE (UK) guidelines are to offer terlipressin to patients with suspected variceal bleeding at presentation and the WGO recommend it as the first choice for pharmacological therapy to control bleeding and mortality.
Terlipressin EVER Pharma was developed to offer a more convenient and safer to use product than the originator Glypressin®.
Available as a ready to use solution in a vial, there is no need to either reconstitute the product with solvent or break open ampoules. Both initial and maintenance dose ranges are conveniently and economically covered by providing a 10mL vial in addition to the current 5ml vial.
Currently registered in 10 European countries with further registrations in progress or planned globally.
- Ready to use product – for immediate use without reconstitution
- Available in vials – safer and more convenient than ampoules
- 5ml and new 10ml presentation – covering initial and maintenance dose ranges
- Additional indication – for Hepato-renal syndrome type 1